Unipolar Depression Clinical Trial
Official title:
Thinking Healthy Program - Peer Delivered, India (THPP-I)
Background The rates of perinatal depression in South Asian women are reported to be amongst
the highest in the world, ranging from 18%-30% in urban areas and 28%-36% in rural areas. In
addition to its profound impact on women's health, disability and functioning, perinatal
depression is associated with poor child health outcomes such as pre-term birth, infant
under-nutrition and stunting. There is robust evidence that perinatal depression can be
effectively managed with psychological treatments delivered by non-specialist health care
workers. The Thinking Healthy Program (THP), a psychological treatment delivered by community
health workers (CHWs) in Pakistan, more than halved the rate of perinatal depression among
mothers and led to significant improvements in child health outcomes. To enhance access to
such evidence-based psychological treatments there is a need to examine the potential role of
other human resources such as lay persons in delivering psychological treatments such as THP
in poor resource settings.
Objective To evaluate the effectiveness and cost-effectiveness of THP delivered by peers (the
Thinking Healthy Program-Peer delivered in Goa, India; THPP-I) over the duration of 6 months.
Peers will be healthy mothers who live in the same community as potential trial participants
(TPs).
Study design and outcomes Individual randomized controlled trial in Goa, India involving 280
women. TPs will not be blinded to treatment allocation. Mothers attending antenatal clinics
at hospitals will be assessed for eligibility to participate in the trial (e.g. whether they
are in the second or third trimester of pregnancy). Those who are eligible will be invited to
participate in screening for depression; mothers who consent will be screened for depression
with a locally validated version of the Patient Health Questionnaire (PHQ-9). Women who
screen positive (PHQ-9 score ≥ 10) and give informed consent for further participation in the
trial will be randomly allocated in a 1:1 ratio to receive enhanced usual care (EUC) or
THPP-I+EUC, using a computer generated allocation sequence. The primary outcomes will be
remission (i.e. recovery from depression and depressive symptoms), both assessed by the PHQ-9
at 6 months. Secondary outcomes are depressive symptoms and remission at 3 months (PHQ-9),
maternal disability at 3 and 6 months (measured with the WHO-DAS), perceived social support,
breastfeeding rates and infant weight and height of children at 3 and 6 months. Outcomes will
be analyzed on an intention to treat basis.
Interventions EUC will comprise communicating the results of the screening to the mother
through an information sheet on self-care for mental health, communicating the results to the
mother's gynaecologist, providing the gynaecologist with the WHO mhGAP guidelines for the
treatment of depression, and providing guidance on referral of depressed mothers to mental
health services. TPs who are in the THPP-I group will receive, in addition to EUC, between 6
to 14 sessions of THPP starting from their recruitment in the second/ third trimester until
up to 6 months after child birth. Sessions will be delivered by peers on an individual basis
at a location of convenience to the TPs (usually at their own homes).
Implications THPP-I has the potential to advance knowledge of the extent to which
task-shifting of the delivery of evidence-based psychological treatments can be extended to
peers in the community. If effectiveness is observed, this approach offers a potential
opportunity to access a vast untapped human resource for maternal mental health care and
addresses a major barrier in global mental health - the lack of skilled and motivated human
resources in the formal health sector - offering a new avenue for the scaling up of
evidence-based psychological treatments and mental health services in low resourced settings.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
Completed |
NCT02111915 -
Thinking Healthy Program - Peer Delivered (Pakistan)
|
N/A | |
Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
Completed |
NCT03268434 -
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
|
N/A | |
Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
Completed |
NCT04420793 -
Voice Changes During ECT
|
||
Not yet recruiting |
NCT01694030 -
Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study
|
Phase 1 |